Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-.beta.
AssigneeCetus Corporation
InventorsDavid F. Mark, Leo S. Lin, Shi-Da Yu Lu
Life of this patent
Estimating the term…
Abstract
A modified IFN-.beta. is provided wherein the cysteine residue at position 17 is deleted and serine is substituted therefor. DNA sequences coding for the modified protein, nucleotide primers used for the mutagenesis, appropriate cloning vectors, host organisms transformed with the vectors, methods for the production and use of the modified IFN-.beta. (IFN-.beta..sub.ser17) are also provided. The specific activity of IFN-.beta..sub.ser17 is found to be substantially the same as that of native IFN-.beta..
Claims15
A structural gene having a DNA sequence that encodes a synthetic IFN-.beta. wherein the cysteine residue at position 17, numbered in accordance with native human IFN-.beta., is replaced by a neutral amino acid.
The structural gene as represented in FIG. 10, with or without the initial ATG codon.
The plasmid having an NRRL accession number B-15356.
A host cell transformed with an expression vector that includes a structural gene having a DNA sequence that encodes a synthetic IFN-.beta. wherein the cysteine residue at position 17, numbered in accordance with native human IFN-.beta., is replaced by a neutral amino acid and said mutein exhibits the biological activity of native human IFN-.beta., wherein the host cell is selected from the group consisting of bacteria, yeast, animal, and plant.
E. coli transformed by an expression vector which includes the structural gene represented by FIG. 10, with or without the initial ATG codon.
E. coli transformed with the plasmid pSY2501 and progeny thereof.
Dependencies are inferred from the claim text.